RLM.L Regulatory News (RLM)

13 Sep 2006 07:03

PuriCore Plc13 September 2006 PuriCore Announces the Appointment of Three New Independent Non-Executive Directors MALVERN, PENNSYLVANIA, and STAFFORD, UK, 13 September 2006 -- PuriCore plc("PuriCore") (London Stock Exchange: PURI), the developer of a novel, safetechnology that mimics the human body's natural anti-microbial, hypochlorousacid, today announces the appointment of three new independent non-executivedirectors. Timothy Anderson Mr. Anderson, 60, held various executive management positions at BaxterInternational (NYSE: BAX), a leading US medical technology company, from 1972 to2002, including Senior Vice President of Strategy and Business Development from1999 until 2002, President, Biotech Group from 1992 until 1997, Group VicePresident from 1993 until 1997 and Chairman, Baxter Europe from 1997 until 1999.He continues to be a member of Baxter's Scientific Advisory Board. Mr.Anderson is also currently a Director of Cerus Corporation (NASDAQ: CERS), TecanAG (Swiss: TECN), and Lake Forest Hospital. Mr Anderson will also be a memberof the PuriCore Audit Committee. Alan Suggett, BSc, PhD, C Chem, FRSC Dr. Suggett, 63, has over 20 years experience operating at the technical/business interface in the medical devices field and he brings great experienceof strategic and governance leadership, most recently related to orthopedics,minimally-invasive surgery, and wound management. Until retiring from hisfull-time operational roles at the beginning of 2004, he was Group Director ofTechnology at Smith & Nephew plc and a long-standing member of the Company'sExecutive Committee. Previously he was Group R&D Director at Smith & Nephew andheld senior positions with Scottish & Newcastle Breweries and Unilever Research. Dr. Suggett is also a Non-Executive Director of Intercytex Group plc (AIM:ICX), Chairman of the Scientific Advisory Board of Photopharmica Limited,Chairman of the Healthcare Technologies Knowledge Transfer Network, a Fellow ofthe Royal Society of Chemistry, an Honorary Fellow of the Royal College ofPhysicians, and a Visiting Professor at the University of York. Jim Walsh, PhD Dr. Jim Walsh, 48, has 20 years general management experience in the healthcareindustry with particular experience in diagnostics. He is an Executive Directorand Chief Operating Officer with Trinity Biotech Plc (NASDAQ: TRIB), an Irishheadquartered diagnostics company. Dr. Walsh also holds Non-Executive Directorpositions with a number of early stage companies in the areas of micro-fluidicsand molecular biology. Previously Dr. Walsh was Managing Director of CambridgeDiagnostics Ltd., a wholly owned subsidiary of Inverness Medical Innovations Inc(AMEX: IMA). Before joining CDL, he worked with Fleming GmbH as R&D Manager.Born in Ireland, Dr. Walsh is a graduate of the National University of Irelandand holds a Doctorate in Inorganic Chemistry and Post Doctorate qualificationsin Immunochemistry. He will also serve on the PuriCore Remuneration Committee. Each of the new independent Non-Executive Directors will receive options topurchase 100,000 shares of PuriCore ordinary shares. Each share option willhave a five year life and vest one-third per year beginning on the firstanniversary of grant. The exercise price shall be five per cent over the marketprice of the Company's ordinary shares on the date of grant. Commenting on the appointments, Chris Wightman, Chairman of PuriCore, said, "These new members of our Board bring valuable expertise and contacts to us inthe life science and medical technology industries. They add valuablecommercial experience and their participation will serve to strengthen furtherthe Board's corporate governance. I look forward to working with them inshaping the future of PuriCore." There are no other details which are required to be disclosed under paragraph9.6.13 R of the Listing Rules of the FSA relative to the respective appointmentsof Messrs Anderson, Suggett and Walsh as Non-Executive Directors of the Company. FOR FURTHER INFORMATION: PuriCore plc Tel: +1 (484) 321-2701Greg Bosch, Chief Executive OfficerKeith A. Goldan, Chief Financial Officer Financial Dynamics Tel: +44 (0) 20 7831 3113David YatesSarah MacLeodJohn Gilbert ABOUT PURICORE PLC PuriCore is a life sciences company focused on the development andcommercialization of its proprietary technology that mimics the production bythe human body of its natural anti-microbial, hypochlorous acid. Hypochlorousacid is highly effective at killing pathogens such as bacteria, viruses andfungi and yet is safe and environmentally friendly. PuriCore's solutions haveapplications in a wide range of markets where it is important to controlmicrobial contamination. These markets include medical device disinfection,food safety, dental equipment decontamination, environmental remediation,hospitality, water safety, wound management and other applications intended tolimit the spread of infectious disease, including major global disease threatssuch as Tuberculosis, MRSA, Influenza, E.coli, Norovirus, HIV, polio, HepatitisA, H.pylori and Legionella. PuriCore markets a portfolio of branded systems which produce hypochlorous acidsolutions on-site at a customer's location from water, electricity and commonsalt. These solutions are generated at a range of concentrations and at anearly neutral pH range similar to the human body. They are effective as soaks,sprays, mists and in other forms. PuriCore is headquartered in Malvern, Pennsylvania and has offices in Stafford,UK. To receive additional information on the Company, please visit our Web site atwww.puricore.com, which does not form part of this press release. This information is provided by RNS The company news service from the London Stock Exchange